This activity is provided by Penn State College of Medicine in partnership with PeerView Institute for Medical Education. Modern acute myeloid leukemia (AML) care has been transformed by a wave of innovative therapeutics that has decisively overturned prior standards of care based exclusively on cytarabine chemotherapy. In the wake of these developments, the safe delivery of different therapeutic drug classes, including FLT3, IDH, and BCL2 inhibitors; novel radioimmunoconjugate approaches; and newer targeted therapeutics (eg, menin inhibitors), has come to define the present and future of AML management. To explore next-level AML care, join PeerView’s expert faculty for this Clinical Consult case-based discussion (based on a live program held at ASH23 and developed in collaboration with HealthTree Foundation for AML) on how to leverage the fruits of new science to improve patient care. Each discussion will address topics such as the use of BCL2 inhibitors in patients with and without targetable mutations, next-generation FLT3i as induction and maintenance options, the emergence of radioimmunoconjugates in challenging AML settings, and the role of inhibitors for difficult-to-treat AML.